Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Subscribe

Logo for

PNAS 102 (7): 2543-2548

Copyright © 2005 by the National Academy of Sciences.

MEDICAL SCIENCES

Identification of pathway-selective estrogen receptor ligands that inhibit NF-{kappa}B transcriptional activity

Christopher C. Chadwick * {dagger}, Susan Chippari *, Edward Matelan {ddagger}, Lisa Borges-Marcucci §, Amy M. Eckert *, James C. Keith, Jr. ¶, Leo M. Albert ¶, Yelena Leathurby ¶, Heather A. Harris *, Ramesh A. Bhat *, Mark Ashwell {ddagger} ||, Eugene Trybulski {ddagger}, Richard C. Winneker *, Steven J. Adelman §, Robert J. Steffan {ddagger}, and Douglas C. Harnish §, **

*Women's Health Research Institute and Departments of {ddagger}Chemical and Screening Sciences and §Cardiovascular and Metabolic Disease Research, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426; and Department of Cardiovascular and Metabolic Disease Research, Wyeth Research, 200 Cambridge Park Drive, Cambridge, MA 02140

Edited by Jan-Åke Gustafsson, Karolinska Institute, Huddinge, Sweden

Accepted for publication January 5, 2005.

Received for publication August 9, 2004.

Abstract: Inflammation is now recognized as a key component in a number of diseases such as atherosclerosis, rheumatoid arthritis, and inflammatory bowel disease. The transcription factor NF-{kappa}B has been shown to be involved in both the early and late stages of the inflammatory-proliferative process. In this report, we describe the identification of the pathway-selective estrogen receptor (ER) ligand, WAY-169916, that inhibits NF-{kappa}B transcriptional activity but is devoid of conventional estrogenic activity. This pathway-selective ligand does not promote the classic actions of estrogens such as stimulation of uterine proliferation or ER-mediated gene expression, but is a potent antiinflammatory agent, as demonstrated in the HLA-B27 transgenic rat model of inflammatory bowel disease. Our results indicate the potential utility of pathway-selective ER ligands such as WAY-169916 in the treatment of chronic inflammatory diseases.

Key Words: inflammation • therapy

Author contributions: C.C.C., J.C.K., H.A.H., E.T., R.C.W., S.J.A., R.J.S., and D.C.H. designed research; C.C.C., S.C., E.M., L.B.-M., A.M.E., J.C.K., L.M.A., Y.L., H.A.H., M.A., R.J.S., and D.C.H. performed research; E.M., R.A.B., and R.J.S. contributed new reagents/analytic tools; C.C.C., S.C., E.M., L.B.-M., A.M.E., J.C.K., L.M.A., Y.L., H.A.H., R.J.S., and D.C.H. analyzed data; and D.C.H. wrote the paper.

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: ER, estrogen receptor; IBD, inflammatory bowel disease; E2, 17{beta}-estradiol; EE, 17{alpha}-ethynylestradiol; CK, creatine kinase; ICI, ICI 182,780; HAECT-1, human aorta endothelial cell 1.

{dagger} Present address: Life Diagnostics Inc., 909 Old Fern Hill Road, West Chester, PA 19380.

|| Present address: ArQule Research, 19 Presidential Way, Woburn, MA 01801.

** To whom correspondence should be addressed. E-mail: harnisd{at}wyeth.com.

© 2005 by The National Academy of Sciences of the USA

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Targeting estrogen receptor {beta} in microglia and T cells to treat experimental autoimmune encephalomyelitis.
W.-f. Wu, X.-j. Tan, Y.-b. Dai, V. Krishnan, M. Warner, and J.-A. Gustafsson (2013)
PNAS 110, 3543-3548
   Abstract »    Full Text »    PDF »
Mechanisms of sex disparities in influenza pathogenesis.
S. L. Klein, A. Hodgson, and D. P. Robinson (2012)
J. Leukoc. Biol. 92, 67-73
   Abstract »    Full Text »    PDF »
Estrogen Receptor Expression Is Required for Low-Dose Resveratrol-Mediated Repression of Aryl Hydrocarbon Receptor Activity.
G. H. Perdew, B. D. Hollingshead, B. C. DiNatale, J. L. Morales, M. P. Labrecque, M. K. Takhar, K. J. Tam, and T. V. Beischlag (2010)
J. Pharmacol. Exp. Ther. 335, 273-283
   Abstract »    Full Text »    PDF »
Estradiol inhibits ongoing autoimmune neuroinflammation and NF{kappa}B-dependent CCL2 expression in reactive astrocytes.
S. N. Giraud, C. M. Caron, D. Pham-Dinh, P. Kitabgi, and A. B. Nicot (2010)
PNAS 107, 8416-8421
   Abstract »    Full Text »    PDF »
Evidence for Ligand-Mediated Selective Modulation of Aryl Hydrocarbon Receptor Activity.
I. A. Murray, J. L. Morales, C. A. Flaveny, B. C. DiNatale, C. Chiaro, K. Gowdahalli, S. Amin, and G. H. Perdew (2010)
Mol. Pharmacol. 77, 247-254
   Abstract »    Full Text »    PDF »
Convergence of Hormones, Inflammation, and Energy-Related Factors: A Novel Pathway of Cancer Etiology.
M. L. Slattery and F.A. Fitzpatrick (2009)
Cancer Prevention Research 2, 922-930
   Abstract »    Full Text »    PDF »
Role of SP transcription factors in hormone-dependent modulation of genes in MCF-7 breast cancer cells: microarray and RNA interference studies.
F. Wu, I. Ivanov, R. Xu, and S. Safe (2009)
J. Mol. Endocrinol. 42, 19-33
   Abstract »    Full Text »    PDF »
CBP Is a Dosage-Dependent Regulator of Nuclear Factor-{kappa}B Suppression by the Estrogen Receptor.
K. W. Nettles, G. Gil, J. Nowak, R. Metivier, V. B. Sharma, and G. L. Greene (2008)
Mol. Endocrinol. 22, 263-272
   Abstract »    Full Text »    PDF »
Vascular Endothelial Growth Factor Receptor-2 Expression Is Down-Regulated by 17{beta}-Estradiol in MCF-7 Breast Cancer Cells by Estrogen Receptor {alpha}/Sp Proteins.
K. J. Higgins, S. Liu, M. Abdelrahim, K. Vanderlaag, X. Liu, W. Porter, R. Metz, and S. Safe (2008)
Mol. Endocrinol. 22, 388-402
   Abstract »    Full Text »    PDF »
Selective Estrogen Receptor- Agonists Repress Transcription of Proinflammatory Genes.
A. Cvoro, D. Tatomer, M.-K. Tee, T. Zogovic, H. A. Harris, and D. C. Leitman (2008)
J. Immunol. 180, 630-636
   Abstract »    Full Text »    PDF »
The Complex Role of Estrogens in Inflammation.
R. H. Straub (2007)
Endocr. Rev. 28, 521-574
   Abstract »    Full Text »    PDF »
Oestrogens inhibit interleukin 1{beta}-mediated nitric oxide synthase expression in articular chondrocytes through nuclear factor-{kappa}B impairment.
P. Richette, M.-F. Dumontier, K. Tahiri, M. Widerak, A. Torre, M. Benallaloua, F. Rannou, M.-T. Corvol, and J.-F. Savouret (2007)
Ann Rheum Dis 66, 345-350
   Abstract »    Full Text »    PDF »
Induction of Osteoblast Differentiation by Selective Activation of Kinase-Mediated Actions of the Estrogen Receptor.
S. Kousteni, M. Almeida, L. Han, T. Bellido, R. L. Jilka, and S. C. Manolagas (2007)
Mol. Cell. Biol. 27, 1516-1530
   Abstract »    Full Text »    PDF »
International Union of Pharmacology. LXIV. Estrogen Receptors.
K. Dahlman-Wright, V. Cavailles, S. A. Fuqua, V. C. Jordan, J. A. Katzenellenbogen, K. S. Korach, A. Maggi, M. Muramatsu, M. G. Parker, and J.-A. Gustafsson (2006)
Pharmacol. Rev. 58, 773-781
   Full Text »    PDF »
Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies.
J. L. Turgeon, M. C. Carr, P. M. Maki, M. E. Mendelsohn, and P. M. Wise (2006)
Endocr. Rev. 27, 575-605
   Abstract »    Full Text »    PDF »
Selective Agonists of Estrogen Receptor Isoforms: New Perspectives for Cardiovascular Disease.
C. Bolego, E. Vegeto, C. Pinna, A. Maggi, and A. Cignarella (2006)
Arterioscler Thromb Vasc Biol 26, 2192-2199
   Abstract »    Full Text »    PDF »
The Nuclear Hormone Receptor Farnesoid X Receptor (FXR) Is Activated by Androsterone.
S. Wang, K. Lai, F. J. Moy, A. Bhat, H. B. Hartman, and M. J. Evans (2006)
Endocrinology 147, 4025-4033
   Abstract »    Full Text »    PDF »
Crossroads of Estrogen Receptor and NF-{kappa}B Signaling.
D. K. Biswas, S. Singh, Q. Shi, A. B. Pardee, and J. D. Iglehart (2005)
Sci. STKE 2005, pe27
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882